U.S. Media Covid-19 Stories More Negative than World Media Stories and than Scientific Journal Stories

(p. A8) Bruce Sacerdote, an economics professor at Dartmouth College, noticed something last year about the Covid-19 television coverage that he was watching on CNN and PBS. It almost always seemed negative, regardless of what was he seeing in the data or hearing from scientists he knew.

When Covid cases were rising in the U.S., the news coverage emphasized the increase. When cases were falling, the coverage instead focused on those places where cases were rising. And when vaccine research began showing positive results, the coverage downplayed it, as far as Sacerdote could tell.

But he was not sure whether his perception was correct. To check, he began working with two other researchers, building a database of Covid coverage from every major network, CNN, Fox News, Politico, The New York Times and hundreds of other sources, in the U.S. and overseas. The researchers then analyzed it with a social-science technique that classifies language as positive, neutral or negative.

The results showed that Sacerdote’s instinct had been right — and not just because the pandemic has been mostly a grim story.

The coverage by U.S. publications with a national audience has been much more negative than coverage by any other source that the researchers analyzed, including scientific journals, major international publications and regional U.S. media. “The most well-read U.S. media are outliers in terms of their negativity,” Molly Cook, a co-author of the study, told me.

About 87 percent of Covid coverage in national U.S. media last year was negative. The share was 51 percent in international media, 53 percent in U.S. regional media and 64 percent in scientific journals.

For the full commentary, see:

David Leonhardt. “The Pandemic Is a Grim Story, but is Bad news the Only Kind?” The New York Times (Wednesday, March 24, 2021): A8.

(Note: the online version of the commentary has the same date as the print version, and has the title “Bad News Bias.”)

The study discussed above is:

Sacerdote, Bruce, Ranjan Sehgal, and Molly Cook. “Why Is All Covid-19 News Bad News?” National Bureau of Economic Research, NBER Working Paper #28110, Nov. 2020.

Distinguished French Scientists Spearhead International Effort to Investigate Possible Wuhan Lab Origin of Covid-19

(p. A8) BEIJING—A World Health Organization team investigating the origins of Covid-19 is planning to scrap an interim report on its recent mission to China amid mounting tensions between Beijing and Washington over the investigation and an appeal from one international group of scientists for a new probe.

The group of two dozen scientists is calling in an open letter on Thursday [March 4,2021] for a new international inquiry. They say the WHO team that last month completed a mission to Wuhan—the Chinese city where the first known cases were found—had insufficient access to adequately investigate possible sources of the new coronavirus, including whether it slipped from a laboratory.

. . .

WHO chief Tedros Adhanom Ghebreyesus said on Feb. 12 [2021] that the team would release an interim report briefly summarizing the Wuhan mission, possibly the following week, with a full report coming weeks later. But that summary report has yet to be published and the WHO team is now scrapping that plan, said Peter Ben Embarek, the food-safety scientist who led the team.

. . .

According to an advance copy of the open letter, the group of 26 scientists and other experts in areas including virology, zoology and microbiology said that it was “all but impossible” for the WHO team to conduct a full investigation, and that any report was likely to involve political compromises as it had to be approved by the Chinese side.

A credible investigation required, among other things, confidential interviews and fuller access to hospital records of confirmed and potential Chinese coronavirus cases in late 2019, when the outbreak was first identified in Wuhan, said the letter signed by experts from France, the U.S., India, Australia and other countries.

Investigators should also be allowed to view records including maintenance, personnel, animal breeding and experiment logs from all laboratories working with coronaviruses, the letter said.

“We cannot afford an investigation into the origins of the pandemic that is anything less than absolutely thorough and credible,” the letter said. “Efforts to date do not constitute a thorough, credible, and transparent investigation.”

The appeal is unlikely to gain traction, as any future probes would require Beijing’s cooperation. Moreover, many leading infectious-disease experts are skeptical that a lab accident could plausibly explain the origins of the pandemic.

Still, it expresses what has become a more widely shared dissatisfaction, voiced by the U.S. and U.K. governments and many scientists world-wide, that China has provided too little information and data to the WHO to guide researchers trying to determine where the virus originated and how it jumped to humans.

. . .

A laboratory accident is “definitely not off the table,” Dr. Ben Embarek told a seminar last week. Dr. Tedros said in February after the team’s trip that “all hypotheses remain open and require further analysis.”

The signatories of the open letter are mostly members of a broader group, spearheaded by French scientists, who have been sharing research papers and other information on Covid-19 since around December. None are associated with the WHO investigation.

Among the signatories are Etienne Decroly and Bruno Canard, molecular virologists at AFMB Lab, which belongs to Aix-Marseille University and the French National Centre for Scientific Research, France’s state research agency.

Dr. Decroly said he became involved after concluding that on the basis of available data, it was impossible to determine whether SARS-CoV-2 “is the result of a zoonosis from a wild viral strain or an accidental escape of experimental strains.”

The letter was co-organized by Gilles Demaneuf, a French data scientist based in New Zealand, and Jamie Metzl, a U.S.-based senior fellow for the Atlantic Council and adviser to the WHO on human genome editing.

Prominent critics of the laboratory hypothesis have in recent weeks published new research on bat coronaviruses found in Southeast Asia and Japan that they say shows that SARS-CoV-2 most likely evolved naturally to infect humans.

Robert Garry, a virologist at the Tulane University School of Medicine who was involved in that research, said he and other colleagues had initially considered the possibility of a leak or accident from a laboratory, but ultimately deemed it “nearly impossible.”

The Biden administration hasn’t publicly repeated its predecessor’s specific assertions regarding Wuhan laboratories.

Signatories of the open letter say they don’t back any one hypothesis but think it is premature to exclude the possibility of a leak or accident at or connected with a research facility such as the Wuhan Institute of Virology, or WIV, which runs high-security laboratories and has conducted extensive research on bat coronaviruses.

WIV scientists deny the virus came from there, saying they neither stored nor worked on SARS-CoV-2 before the pandemic and none of their staff tested positive for the virus.

Signatories said investigators should look at several possible scenarios, including whether a laboratory employee became infected with a naturally evolving virus while sampling bats in the wild, during transport of infected animals, or during disposal of lab waste.

They also said investigators should probe whether SARS-CoV-2 could have stemmed from “gain-of-function” experiments, in which viruses found in the wild are genetically manipulated to see if they can become more infectious or deadly to humans.

For the full story, see:

Betsy McKay, Drew Hinshaw, and Jeremy Page. “WHO Delays Release of Virus Origin Report.” The Wall Street Journal (Friday, March 5, 2021): A8.

(Note: ellipses, and bracketed dates, added.)

(Note: the online version of the story was updated March 5, 2021, and has the title “WHO Investigators to Scrap Plans for Interim Report on Probe of Covid-19 Origins.” The online edition says that the title in the print edition was “WHO Team Delays Release of Report on Virus’s Origin.” But my copy of the print edition had the title “WHO Delays Release of Virus Origin Report.”
The last 11 paragraphs quoted above appear in the online version, but not the print version, of the article.)

The open letter mentioned above, signed by 26 scientists from Australia, Austria, Belgium, France, Germany, India, New Zealand, Spain, the United Kingdom, and the United States, is:

Butler, Colin D., Bruno Canard, Henri Cap, Y. A. Chan, Jean-Michel Claverie, Fabien Colombo, Virginie Courtier, Francisco A. de Ribera, Etienne Decroly, Rodolphe de Maistre, Gilles Demaneuf, Richard H. Ebright, André Goffinet, François Graner, José Halloy, Milton Leitenberg, Filippa Lentzos, Rosemary McFarlane, Jamie Metzl, Dominique Morello, Nikolai Petrovsky, Steven Quay, Monali C. Rahalkar, Rossana Segreto, Günter Theißen, and Jacques van Helden. “Open Letter: Call for a Full and Unrestricted International Forensic Investigation into the Origins of Covid-19.” March 4, 2021.

Raising Minimum Wage to $15 Will Likely Cause 16% Rise in Low-Skilled Job Loss

(p. A15) A recent Congressional Budget Office report estimated that 1.4 million jobs would be lost if a new $15 federal minimum wage is signed into law. Advocates were quick to dismiss the CBO’s conclusion. “It is not a stretch to say that a new consensus has emerged among economists that minimum wage increases have raised wages without substantial job loss,” said Heidi Shierholz of the Economic Policy Institute, which has also circulated a letter signed by economics Nobel laureates and others making the same claim.

. . .

To provide an accurate reading of the research, Peter Shirley and I surveyed the authors of nearly all U.S. studies estimating the effects of minimum wages on employment published in the past 30 years. We asked them to report to us their best estimate of the employment effect, measured as the “elasticity,” or the percent change in employment for each 1% change in the minimum wage. Most authors responded, and in the few cases in which they did not, we pulled this estimate from their study.

The results are stark. Across all studies, 79% report that minimum wages reduced employment. In 46% of studies the negative effect was statistically significant. In contrast, only 21% of studies found small positive effects of minimum wages on employment, and in only a minuscule percentage (4%) was the evidence statistically significant. A simplistic but useful calculation shows that the odds of nearly 80% of studies finding negative employment effects if the true effect is zero is less than one in a million.

Across all the studies, the average employment elasticity is about minus-0.15, which means, for example, that a 10% increase in the minimum wage reduces employment of the low-skilled by 1.5%. Extrapolating this to a $15 minimum wage, this 107% increase in the states where the federal minimum wage of $7.25 now prevails would imply a 16% decline in low-skilled employment (broadly consistent with the recent CBO study). That sounds like a substantial job loss.

For the full commentary, see:

David Neumark. “Raising the Minimum Wage Definitely Costs Jobs.” The Wall Street Journal (Friday, March 19, 2021): A15.

(Note: ellipsis added.)

(Note: the online version of the commentary has the date March 18, 2021, and has the title “Raising the Minimum Wage Will Definitely Cost Jobs.”)

Chinese Atlases Are Shrugging

(p. B4) SINGAPORE—Chinese e-commerce company Pinduoduo Inc.’s founder and chairman, Colin Huang, stepped down from the company on Wednesday [March 17, 2021], even as the five-year-old company overtook Alibaba Group Holding Ltd. to become the country’s largest e-commerce company by annual active buyers.

Mr. Huang, 41 years old, is resigning as China’s powerful internet sector comes under growing government scrutiny. His resignation follows another departure from a major company in the sector: Financial-tech giant Ant Group Co.’s Chief Executive Simon Hu stepped down earlier this month.

. . .

Beijing in recent months has been moving to rein in China’s powerful internet sector including e-commerce companies. Among the hardest hit has been Alibaba, which is under antitrust probe; its fintech affiliate Ant, whose initial public offering was canceled in November [2020]; and its founder Jack Ma.

This month, Chinese regulators fined Pinduoduo, alongside several other e-commerce companies, alleging anticompetitive practices.

For the full story, see:

Keith Zhai. “Head of China’s Giant E-Commerce Firm Quits.” The Wall Street Journal (Thursday, March 18, 2021): B4.

(Note: ellipsis, and bracketed dates, added.)

(Note: the online version of the story was updated March 17, 2021, and has the title “Pinduoduo Founder Colin Huang Steps Down From Company.”)

The fictional version is:

Rand, Ayn. Atlas Shrugged. New York: Random House, 1957.

Rebates to Formulary Middlemen Are a Growing Part of Drug Costs

(p. B14) To actually sell medication, a drugmaker needs to persuade public and private health plans to place their product on the plan’s formulary, which is a list of drugs the plan is willing to purchase. That means paying middlemen rebates and discounts to choose their drug over any other rival treatments. Failure to secure favorable formulary access could mean low sales even for a highly-effective and safe medication..

. . .

“To secure that formulary position costs us more and more every year,” said Adam Gluck, Sanofi’s head of U.S. corporate affairs, in an interview. The company says that the average list price for its insulin products is up 141% since 2012 but that the net price is down 53% over that same period.

It isn’t just Sanofi facing this dynamic. Merck & Co. said last month that its average U.S. sticker price rose 3.1% in 2020 even as its average net price fell slightly. That is a sea change from recent years: In both 2015 and 2016 Merck’s average list price rose by about 10% while the net price realized by the drug giant rose by 5.5%. Nearly half of Merck’s gross sales went out the door to third parties as discounts last year. A decade ago, that tally was around 27%. Other drugmakers like Bristol-Myers Squibb report similarly high spreads between gross and net sales.

For the full commentary, see:

Charley Grant. “Pharma Giants Are Getting Their Pennies Pinched.” The Wall Street Journal (Saturday, March 13, 2021): B14.

(Note: ellipsis added.)

(Note: the online version of the commentary was updated March 12, 2021, and has the title “Pharma Giants Get Their Pennies Pinched on Drug Pricing.”)

“It’s Taken Me 27 Years to Become an Overnight Sensation”

(p. B1) The flashiest trend in finance traces back three decades to a pair of old law-school buddies. Now, they are finally cashing in.

Investment banker David Nussbaum and lawyer David Miller —known to each other as “Nuss” and “Miller”—invented the special-purpose acquisition company in 1993 to give private firms another way to access everyday investors.

. . .

“It’s taken me 27 years to become an overnight sensation,” said Mr. Nussbaum, a 66-year-old from Roslyn, N.Y., on Long Island, who co-founded the SPAC-focused investment bank EarlyBirdCapital Inc.

. . .

(p. B5) Many on Wall Street were suspicious of SPACs because their predecessors were called “blind pools” and tied to penny-stock fraud in the 1980s.

. . .

In the early 1990s, the Davids spent over a year working with regulators to install protections for investors and other changes to prevent fraud before completing the first blank-check firm. Among them were the right for a SPAC’s investors to get their money back before a merger with a private company goes through. They also beefed up disclosure requirements ahead of such deals. Those features are now touted by blank-check company bulls.

Still, SPACs struggled to compete with traditional initial public offerings and other methods for raising money until splashy names like sports-betting firm DraftKings Inc. started using them to go public in recent years and more startups began using them to make projections to investors—something that isn’t allowed in a traditional IPO.

“It’s become bigger than anyone expected,” said Mr. Miller, a 66-year-old from Queens, N.Y., who is managing partner at law firm Graubard Miller . . .

. . .

“I am really happy for them,” said Arthur Spector, a venture capitalist who ran the first SPAC Messrs. Nussbaum and Miller worked on in 1993. “They put in a huge amount of work and from some people took a lot of grief.”

. . .

Both men said they now plan to work until it is no longer fun.

For the full story, see:

Amrith Ramkumar. “Pioneers of SPACs Reap The Rewards.” The Wall Street Journal (Wednesday, March 10, 2021): B1 & B5.

(Note: ellipses added.)

(Note: the online version of the story was updated March 9, 2021, and has the title “SPAC Pioneers Reap the Rewards After Waiting Nearly 30 Years.”)

Freireich on Chemo-Cocktail Cure for Childhood Leukemia: “I Thought About It and I Knew It Would Work”

(p. A20) Dr. Emil Freireich, a renowned cancer doctor and relentless researcher who helped devise treatments for childhood leukemia that transformed the lives of patients thought to have little hope of survival, died on Feb. 1 [2021] at the University of Texas MD Anderson Cancer Center in Houston, where he had worked since 1965.

. . .

When Dr. Freireich (pronounced FRY-rike) started work at the N.C.I., in Bethesda, Md., in 1955, acute childhood leukemia was considered a death sentence. Entering the ward where the children were being treated, he recalled their hemorrhaging because their blood had virtually no platelets, the disc-shaped cells that clot blood.

. . .

Dr. Freireich, a hematologist and oncologist, tested his hypothesis that the lack of platelets was causing the hemorrhaging by mixing some of his own blood with some of the children’s.

“Would it behave normally?” he said in interview for an N.C.I. oral history project in 1997. “Sure enough, it did.”

Further testing, done to persuade his skeptics at the cancer institute, proved him right.

. . .

. . . Dr. Freireich’s most important and most enduring achievement was in using a combination of drugs to send leukemia into remission. He explored options in chemotherapy with several N.C.I. colleagues, including Dr. Emil Frei III, who was known as Tom.

They made an aggressive assault on childhood leukemia by devising a cocktail of four drugs that would be administered simultaneously — a technique similar to the three-drug regimen used to treat tuberculosis — so that each one would attack a different aspect of the physiology of the cancer cells.

“It was crazy,” Dr. Freireich told Mr. Gladwell. “But smart and correct. I thought about it and I knew it would work. It was like the platelets. It had to work!”

But not without peril and concern. Some of the children nearly died from the drugs. Critics called Dr. Freireich inhumane for experimenting with his young patients.

“Instead, 90 percent went into remission immediately,” he told USA Today in 2015. “It was magical.” But temporary. One round of the cocktail was not enough to eliminate all the cancer, so Dr. Freireich and his team treated them with the drugs monthly for more than a year.

. . .

Dr. Freireich compared his early fight to cure childhood leukemia to being in a battle in which he and the N.C.I. team had an alliance that was “forged under fire.”

To cure cancer, he added: “Motivate people and give them the opportunity. People are innately motivated. Nobody likes to be lazy and do nothing. Everybody wants to be significant.”

For the full obituary, see:

Richard Sandomir. “Emil Freireich, 93, Pioneering Researcher and Cancer Doctor, Is Dead.” The New York Times (Saturday, February 13, 2021): A20.

(Note: ellipses, and bracketed year, added.)

(Note: the online version of the obituary was updated Feb. 8, 2021, and has the title “Emil Freireich, Groundbreaking Cancer Researcher, Dies at 93.”)

Malcolm Gladwell devoted a chapter to Freireich in Gladwell’s book:

Gladwell, Malcolm. David and Goliath: Underdogs, Misfits, and the Art of Battling Giants. New York, NY: Little, Brown and Company, 2013.

Video of Diamond Q&A on Innovation Unbound Posted to YouTube

On 3/17/21 Derek Yonai posted my 3/16/21 live Q&A session related to my “Innovation Unbound” lecture that was recorded on 3/1/21 and posted on 3/9/21. Some of my lecture and some of my answers in the Q&A, were related to my book:

Diamond, Arthur M., Jr. Openness to Creative Destruction: Sustaining Innovative Dynamism. New York: Oxford University Press, 2019.

Quiet, Modest Steinsberger Said Scientists Should “Be Interested in Learning About Nature,” Not in Seeking Prizes

(p. B12) Jack Steinberger, who shared the 1988 Nobel Prize in Physics for expanding understanding of the ghostly neutrino, a staggeringly ubiquitous subatomic particle, died on Saturday [Dec. 12, 2020] at his home in Geneva.

. . .

In 1988, The Economist said Dr. Steinberger “enjoys a reputation as one of the finest experimental physicists in the world.” The magazine continued, “In a field full of flamboyance and a fair bit of arrogance, he is a quiet, modest man; something of a physicist’s physicist.”

As if to prove the point, Dr. Steinberger told a meeting of Nobel laureates in 2008 that scientists should “be interested in learning about nature,” not prizes.

“The pretension that some of us are better than others,” he said, “I don’t think is a very good thing.”

For the full obituary, see:

Douglas Martin. “Jack Steinberger, Physicist Awarded a Joint Nobel Prize, Is Dead at 99.” The New York Times (Thursday, December 17, 2020): B12.

(Note: ellipses, and bracketed date, added.)

(Note: the online version of the obituary was updated Jan. 20, 2021, and has the title “Jack Steinberger, Nobel Winner in Physics, Dies at 99.”)

Gerardo Guillén García del Barco Wants to Build in Cuba “Without Being Hindered by Bureaucracy”

(p. A10) HAVANA — Car dealerships, book publishing and hedge funds are still prohibited. Bed-and-breakfasts are not. Zoos, scuba diving centers and weapons production remain banned. Veterinary services aren’t.

As Cuba’s Communist government continues its piecemeal expansion of the fledgling private sector, Cubans are carefully parsing a list of the economic activities that the government proposes to keep under its control.

. . .

The new list seems to open major new space for manufacturing. Cubans will now be able to apply for licenses to open cheese, paint and toy factories, for example, though the government has not yet defined the permitted size of such ventures.

While some Cubans hailed the list as an important step forward in the country’s economic liberalization, it left others complaining that the government had not gone far enough.

“It’s messed up,” said Gerardo Guillén García del Barco, 26, an architect in Havana whose profession the government plans to maintain under its sole control. “Every time something appears that looks like a panacea, it ends in nothing.”

“My dream is to do exactly what I’m doing today but within a legal framework,” he said, explaining that he left a government firm and now works freelance without a license. “I want to do my own architecture without being hindered by bureaucracy.”

. . .

Last Saturday [Feb. 6, 2021], in announcing the planned expansion of private economic activity, Marta Elena Feitó, Cuba’s labor and social security minister, said that the changes would “unleash the productive forces” of the population.

For the full story, see:

Ed Augustin and Kirk Semple. “Cubans Study a Shrinking List of Prohibited Private Enterprises.” The New York Times (Friday, February 12, 2021): A10.

(Note: ellipses, and bracketed date, added.)

(Note: the online version of the story has the date Feb. 11, 2021, and has the title “Cubans Study a Shrinking List of Banned Private Enterprises.”)

Cancelled Slate Podcaster “Heartsick” That Ideas Cannot Be Debated and Words Cannot Be Spoken

(p. B5) The online publication Slate has suspended a well-known podcast host after he debated with colleagues over whether people who are not Black should be able to quote a racial slur in some contexts.

. . .

Mr. Pesca explored the argument over the use of the slur in a 2019 podcast about a Black security guard who was fired for using it. In one recording of the episode, Mr. Pesca said, he used the term while quoting the man, but asked his producer to make a version without the term. After consultation with his producers and his supervisor, who objected to his quotation of the slur, they decided to go with the version without it, he said.

“The version of the story with the offensive word never aired, and this is how I think the editorial process should go,” Mr. Pesca said in the interview.

No action was taken against him after a human resources investigation into his quotation of the slur, Mr. Pesca said. He said he had apologized to the producers involved.

. . .

Mr. Pesca, who has worked at Slate for seven years, said he was “heartsick” over hurting his colleagues but added, “I hate the idea of things that are beyond debate and things that cannot be said.”

Jacob Weisberg, Slate’s former chairman and editor in chief, who left the company for the podcast start-up Pushkin in 2018, called Mr. Pesca “a huge talent and a fair-minded journalist.”

“I don’t think he did anything that merits discipline or consequences, and I think it’s an example of a kind of overreaction and a lack of judgment and perspective that is unfortunately spreading,” Mr. Weisberg said.

For the full story, see:

Katie Robertson and Ben Smith. “Podcast Host Suspended After Debate Over Slur.” The New York Times (Weds., February 24, 2021): B5.

(Note: ellipses added.)

(Note: the online version of the story has the date Feb. 22, 2021, and has the title “Slate Suspends Podcast Host After Debate Over Racial Slur.”)